Avances en Diabetología - Sociedad Española de Diabetes

20Vol. 21 Núm. 1 - enero-marzo 2005L. Heinemanngies, that a number of new glucose monitoring technologieswill allow development of novel GMS and that the firstattempts will be made to introduce closed-loop systems intothe market (Figure 1). If we expand our view to 10 yearsor even longer, we will see the introduction of the first “Preventionand Cure” biotechnology products and the obsolescenceof most current technologies (insulins, deliveryand diagnostic systems). Clearly this will result in fundamentaltransformation of the current strategies to treatpatients with diabetes.CONSIDERACIONES PRÁCTICAS• Los sistemas disponibles de monitorización continuade glucosa son mínimamente invasivos y permitenregistrar la glucemia sólo durante periodos de tiempolimitado.• Los nuevos sistemas no-invasivos de monitorizacióncontinua de glucosa están todavía en fase de desarrollo.• La introducción de estos nuevos sistemas en la prácticaclínica impondrá necesariamente cambios en lasestrategias actuales de control glucémico.BIBLIOGRAFÍA1. Pfeiffer EF. On the way to the automated (blood) glucose regulationin diabetes: the dark past, the grey present and the rosy future.XII Congress of the International Diabetes Federation, Madrid,22-28 September 1985. Diabetologia 1987; 30: 51-65.2. Maran A, Crepaldi C, Tiengo A, Grassi G, Vitali E, Pagno G, et al.Continuous subcutaneous glucose monitoring in diabetic patients.Diabetes Care 2002; 25: 347-52.3. Lodwig V, Heinemann L on behalf of the Glucose Monitoring StudyGroup. Continuous glucose monitoring with glucose sensors: Calibrationand assessment criteria. Diabetes Technology & Therapeutics2003; 5: 573-88.4. Koschinsky T, Jungheim K, Heinemann L on behalf of the GlucoseMonitoring Study Group. Glucose sensors and the AST-likephenomenon:Relationship between rapid blood glucose changesand glucose sensor signals. Diabetes Technology & Therapeutics2003; 5: 829-42.volver sumario